American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

RIGEL PHARMACEUTICALS INC (RIGL)

$48.13 -1.49% NASDAQ: RIGL · 15-min delayed

SOUTH SAN FRANCISCO, California
Public · NASDAQ: RIGL
174 employees

Visit website Follow

$679.8MMarket cap

$294.3MRevenue · FY2025

$367.0MNet income

174Employees

RIGLNASDAQ

2000IPO

About RIGEL PHARMACEUTICALS INC

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: RIGL
Employees: 174
IPO date: Nov 29, 2000
Headquarters: 611 GATEWAY BOULEVARD, SUITE 900
SOUTH SAN FRANCISCO, California 94080
Phone: 650-624-1100
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Dover, US
Legal entity ID: 529900KPTNUS5J8K9K66

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Registry IDs

Ticker: RIGL Nasdaq
SEC CIK: 1034842
LEI: 529900KPTNUS5J8K9K66
EIN: 943248524
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Rigel Pharmaceuticals Inc’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/rigel-pharmaceuticals-inc/"><img src="https://americancompanies.com/badge/rigel-pharmaceuticals-inc.svg" alt="Rigel Pharmaceuticals Inc — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow RIGEL PHARMACEUTICALS INC and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $294.3M
Net income: $367.0M
Total assets: $513.6M
Market cap: $679.8M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: RIGL

$48.13 -1.49%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$25.44 $50.96

52-week range

Market cap: $679.8M
Shares outstanding: 14.1M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Nov 29, 2000

Rigel Pharmaceuticals Inc (RIGL) Stock Price

Profitable — net income of $367.0M in FY2025.
Trading 6% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review RIGEL PHARMACEUTICALS INC.

Write a review

Newsroom

News about RIGEL PHARMACEUTICALS INC

Reasons Why Investors Should Consider Betting on Arvinas Stock Zacks Investment Research · 2026-10-13 · positive Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate GlobeNewswire Inc. · 2026-09-28 · neutral Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia GlobeNewswire Inc. · 2026-09-01 · positive Thérapeutique Knight annonce l’approbation réglementaire de TAVALISSE® en Colombie GlobeNewswire Inc. · 2026-09-01 · positive Onco360® Has Been Selected as a National Pharmacy Partner for VEPPANU™ (vepdegestrant) GlobeNewswire Inc. · 2026-07-29 · positive Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer Benzinga · 2026-05-12 · positive

News & sentiment via Polygon.io

FAQ

Rigel Pharmaceuticals Inc: frequently asked questions

Is Rigel Pharmaceuticals Inc an American company?

Rigel Pharmaceuticals Inc is a US-based company headquartered in South San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Rigel Pharmaceuticals Inc headquartered?

Rigel Pharmaceuticals Inc is headquartered in South San Francisco, California, United States.

Is Rigel Pharmaceuticals Inc publicly traded?

Yes — Rigel Pharmaceuticals Inc is a publicly traded company. Its stock trades under the ticker symbol RIGL on the NASDAQ.

What does Rigel Pharmaceuticals Inc do?

Rigel Pharmaceuticals Inc is an American Pharmaceuticals company in the Health & Beauty sector.

Explore